Business
Multi-year contract with top five global pharma
Multi-year contract with top five global pharma.
About this update from Diaceutics Plc
[{"type":"text","content":"\n \n \n 13 June 2022\n \n \n \n Diaceutics PLC\n \n \n \n (\"Diaceutics\" or \"the Company\")\n \n \n \n Multi-year contract win with top five global pharma company\n \n \n \n \n US$2m+ contract to deliver customised data insights via the DXRX platform\n \n \n \n Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, intelligence, and analytics on the healthcare market is pleased to announce that it has secured a multi -year deal with a top five global pharma company to deliver customised data insights via the DXRX platform.\n \n \n The three-year enterprise deal, which is in excess of US$2m in aggregate, is a notable upsell win for Diaceutics, which has been working with the client since 2014, and supports the move towards enhanced multi-year recurring revenues, a key strategy for the Company going forward.\n \n \n Under the terms of this new agreement, Diaceutics will provide c\n omprehensive mapping and analysis of US physicians and labs who perform testing for non-small cell lung cancer (NSCLC). This holistic view of the NSCLC space in which labs are performing biomarker specific diagnostic testing means patients can be linked to targeted therapies in this disease area.\n \n \n In addition, Diaceutics will also correlate these labs to corresponding physician testing behaviours, providing an understanding of testing rates, methodologies and the overall relationship between these two key stakeholder groups.\n \n \n \n Jordan Clark, Chief Commercial Officer of Diaceutics commented:\n \n \n \n \n \"This win is testament to the value of our DXRX platform, proving that our platform continues to gain traction within the marketplace, elevating our profile and putting us in a prime position to continue to win large, long-term contracts.\n \n \n \n \n \"As the treatment of cancer has become progressively more biomarker-driven, and with the rapid emergence of effective matched targeted therapies, pharma companies are making attempts to define best practices for which tests are necessary and in what target population. The DXRX intelligence will be a vital tool in enabling our customer to achieve this and optimising their sales territories.\"\n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n \n \n \n Diaceutics PLC\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Nick Roberts, C...